Hospira Vinorelbine Tartrate for Injection 50 mg/5 mL vial

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Disponível em:

Hospira Australia Pty Ltd

DCI (Denominação Comum Internacional):

Vinorelbine tartrate

Forma farmacêutica:

Injection

Composição:

Excipient Ingredients: water for injections

Via de administração:

Intravenous

Unidades em pacote:

1 x 5 mL vial

Classe:

Medicine Listed (Export Only)

Tipo de prescrição:

Not scheduled. Not considered by committee

Indicações terapêuticas:

Vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (NSCLC), as a single agent or in combination. Vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. In addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Resumo do produto:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2008-05-05